Pfizer Inc. $PFE is Liberty One Investment Management LLC's 10th Largest Position

Key Points

• Liberty One Investment Management LLC increased its stake in Pfizer by 11.3% in Q2, now holding 1,225,408 shares, which represents approximately 3.0% of its portfolio, making it the firm's 10th largest position.
• Pfizer is receiving mixed ratings from analysts, with average price targets ranging from $25.00 to $33.00, and an overall average rating of "Hold."
• Pfizer has announced a quarterly dividend of $0.43 per share to be paid on December 1st, 2023, reflecting a 7.0% dividend yield.

Liberty One Investment Management LLC increased its stake in Pfizer Inc. (NYSE:PFE - Free Report) by 11.3% in the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 1,225,408 shares of the biopharmaceutical company's stock after acquiring an additional 123,945 shares during the period. Pfizer comprises approximately 3.0% of Liberty One Investment Management LLC's portfolio, making the stock its 10th largest position. Liberty One Investment Management LLC's holdings in Pfizer were worth $29,704,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. GKV Capital Management Co. Inc. purchased a new stake in Pfizer during the first quarter valued at about $27,000. North Capital Inc. bought a new position in shares of Pfizer during the first quarter valued at about $28,000. Bayforest Capital Ltd bought a new position in Pfizer in the first quarter worth about $28,000. Harbor Asset Planning Inc. purchased a new stake in Pfizer in the second quarter worth about $29,000. Finally, Horizon Financial Services LLC purchased a new stake in Pfizer in the first quarter worth about $35,000. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on PFE shares. Morgan Stanley cut their price objective on shares of Pfizer from $33.00 to $32.00 and set an "equal weight" rating on the stock in a report on Friday, October 10th. Citigroup upped their price objective on shares of Pfizer from $25.00 to $26.00 and gave the stock a "neutral" rating in a report on Wednesday, August 6th. Weiss Ratings restated a "hold (c-)" rating on shares of Pfizer in a report on Wednesday, October 8th. Bank of America increased their price target on shares of Pfizer from $28.00 to $30.00 and gave the company a "neutral" rating in a report on Friday, October 3rd. Finally, UBS Group reiterated a "neutral" rating and set a $28.00 price target on shares of Pfizer in a report on Wednesday, October 1st. Two analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, eleven have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of "Hold" and an average target price of $28.13.

Pfizer Trading Up 0.7%

Shares of PFE stock opened at $24.68 on Tuesday. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $29.22. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65. The firm's 50 day moving average is $24.89 and its 200 day moving average is $24.12. The stock has a market capitalization of $140.33 billion, a P/E ratio of 13.13, a P/E/G ratio of 0.81 and a beta of 0.55.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, beating the consensus estimate of $0.58 by $0.20. The firm had revenue of $14.65 billion for the quarter, compared to the consensus estimate of $13.43 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The company's revenue was up 10.3% on a year-over-year basis. During the same period last year, the firm earned $0.60 EPS. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Research analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, December 1st. Stockholders of record on Friday, November 7th will be given a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 7.0%. The ex-dividend date is Friday, November 7th. Pfizer's dividend payout ratio (DPR) is presently 91.49%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.